CXCL10 and IL-6: Markers of two different forms of intra-amniotic inflammation in preterm labor

Roberto Romero1,2,3,4 | Piya Chaemsaiithong1,5 | Noppadol Chaiyasit1,5 | Nikolina Docheva1,5 | Zhong Dong1,5 | Chong Jai Kim1,6 | Yeon Mee Kim1,7 | Jung-Sun Kim1,8 | Faisal Qureshi1,9 | Suzanne M. Jacques1,9 | Bo Hyun Yoon1,10 | Tinnakorn Chaivorapongsa1,5 | Lami Yeo1,5 | Sonia S. Hassan1,5 | Offer Erez1,5 | Steven J. Korzeniewski1,3,5

1Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD and Detroit, MI, USA
2Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA
3Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA
4Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA
5Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA
6Department of Pathology, University of Ulsan College of Medicine, Seoul, Korea
7Department of Pathology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
8Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9Department of Pathology, Hutzel Women’s Hospital, Wayne State University School of Medicine, Detroit, MI, USA
10Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea

Correspondence
Roberto Romero, MD, D. Med. Sci., and Steven J. Korzeniewski, PhD, Perinatology Research Branch, NICHD/NIH/DHHS, Wayne State University/Hutzel Women’s Hospital, Detroit, MI, USA.
Email: prbchiefstaff@med.wayne.edu and skorzeni@med.wayne.edu

Funding information
Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS), Contract Number: HHSN275201300006C

Problem: To determine whether amniotic fluid (AF) CXCL10 concentration is associated with histologic chronic chorioamnionitis in patients with preterm labor (PTL) and preterm prelabor rupture of the membranes (PROM).

Method of Study: This study included 168 women who had an episode of PTL or preterm PROM. AF interleukin (IL)-6 and CXCL10 concentrations were determined by immunoassay.

Results: (i) Increased AF CXCL10 concentration was associated with chronic (OR: 4.8; 95% CI: 1.7-14), but not acute chorioamnionitis; (ii) increased AF IL-6 concentration was associated with acute (OR: 4.2; 95% CI: 1.3-13.7) but not chronic chorioamnionitis; and (iii) an increase in AF CXCL10 concentration was associated with placental lesions consistent with maternal anti-fetal rejection (OR: 3.7; 95% CI: 1.3-10.4). (iv) All patients with elevated AF CXCL10 and IL-6 delivered preterm.

Conclusion: Increased AF CXCL10 concentration is associated with chronic chorioamnionitis or maternal anti-fetal rejection, whereas increased AF IL-6 concentration is associated with acute histologic chorioamnionitis.

KEYWORDS
allograft, amniocentesis, biomarker, chorioamnionitis, chronic inflammation, cytokine, maternal anti-fetal rejection
1 | INTRODUCTION

Preterm labor is a syndrome characterized by the combination of increased uterine contractility, cervical remodeling (ie, ripening and dilatation), and decidual membrane activation, caused by multiple pathologic processes.1-12 One of the mechanisms of disease implicated in preterm parturition is a breakdown of immune tolerance, which may evolve into maternal anti-fetal rejection.13-30 The fetus and placenta express both maternal and paternal antigens; therefore, they are semiallografts.31-42 The placenta is considered to be the most successful transplant in nature, a biological adaptation accomplished by immune tolerance.43-48 Tolerance is a specific immunological term that refers to “the active state of antigen-specific non-responsiveness”49 leading to diminished reactivity to paternal antigens expressed by the placenta and/or fetus; it is considered key for successful pregnancy.31,33,39,40,50-53 The mechanisms responsible for tolerance in pregnancy include the following: (i) T-cell chemokine gene silencing in the decidual cells;54 (ii) a suppressive role of regulatory T cells;52,55-64 (iii) expression of non-classical major histocompatibility complex molecules on trophoblast cells that do not elicit a maternal immune response;65-70 (iv) changes in tryptophan catabolism;71-75 (v) T-cell apoptosis;76,77 (vi) complement;78-90 and (vii) costimulatory molecules such as the programmed death ligand.91-93 Other mechanisms for tolerance are not currently understood. The interested reader is referred to recent contributions by Sing Sing Way’s laboratory28,39,94-96 and Adrian Erlebacher.31,42,53

In transplantation medicine, failure of tolerance is responsible for graft rejection characterized by an infiltration of the recipient’s CD8+ (cytotoxic) T cells into the graft and an overexpression of C-X-C motif chemokine 10 (CXCL10), a marker of allograft rejection.97-102 In obstetrics, rejection as a mechanism of disease has been largely overlooked. However, recent evidence suggests that maternal anti-fetal rejection is operative in a subset of patients with spontaneous preterm labor,15,16,20,30 preterm prelabor rupture of the membranes (PROM),20 fetal death,7,25 recurrent abortion,19 and other obstetrical syndromes.14,18,21-24,103 Maternal lymphocytes (akin to a transplant recipient) can infiltrate the chorionic placental membranes (fetal tissue or semiallograft), lead to chronic chorioamnionitis,15,26 and induce trophoblast apoptosis, which, when excessive, can result in graft failure (eg, membrane rupture or activation of the decidual membrane and the initiation of labor).15,104 The chemotactic signal inducing the migration of maternal T lymphocytes into the chorionic placental membranes appears to be present in the amniotic cavity. One such chemokine is CXCL10.15,104,105 and an increased concentration of this chemokine in the amniotic fluid has been characterized by our group to represent a distinct form of intra-amniotic inflammation, which is associated with chronic inflammatory lesions of the placenta and a novel form of fetal inflammatory response syndrome (FIRS) or FIRS type 2.21

This distinct form of intra-amniotic inflammation differs from the intra-amniotic inflammatory process observed in patients with preterm labor due to microbial invasion of the amniotic cavity (MIAC). Microorganisms and their products can induce a robust intra-amniotic inflammatory response characterized by an elevation in amniotic fluid interleukin (IL)-6 concentration,106-130 and neutrophil chemokines, such as IL-8,111-113,131-140 as well as other inflammatory mediators capable of inducing the onset of labor.118,135,141-146 Recently, we provided an analysis of the protein inflammatory network for this condition.181 The histologic hallmark of MIAC is acute histologic chorioamnionitis, defined by the infiltration of maternal neutrophils into the chorioamnion membranes.109,182-196 Related lesions are chorionic vasculitits197 and the spectrum of lesions observed in cases of funisitis.155,196,198-204 Therefore, at this time, at least two major types of intra-amniotic inflammation appear to occur in the context of spontaneous preterm labor—one associated with MIAC or induced by danger signals124,205-209 and the other associated with chronic inflammatory lesions of the placenta (often attributed to maternal anti-fetal rejection).

The concentration of the T-cell chemokine CXCL10 (IP-10) is considered a marker for chronic inflammatory lesions associated with allograft rejection and chronic chorioamnionitis in the case of pregnancy. In contrast, IL-6, IL-8, IL-1, and TNF-α are examples of cytokines involved in acute inflammatory lesions of the placenta.109,128,130,196,210

The objective of this study was to determine the prevalence and clinical significance of an elevated CXCL10 concentration in the amniotic fluid of patients with a diagnosis of either preterm labor with intact membranes or preterm PROM and whether an elevation in CXCL10 concentration is associated with chronic chorioamnionitis, as an increased concentration of IL-6 and CXCL10 is frequently observed in patients with intra-amniotic infection and acute histologic chorioamnionitis.

2 | MATERIALS AND METHODS

2.1 | Study population

A nested retrospective cohort study was conducted by searching the clinical database and Bank of Biological Materials of Wayne State University, the Detroit Medical Center, and the Perinatology Research Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (Detroit, MI) to identify patients with a diagnosis of spontaneous preterm labor with intact membranes or preterm PROM. Patients were included if they met the following criteria: (i) singleton gestation; (ii) episode of preterm labor and intact or ruptured membranes; and (iii) transabdominal amniocentesis performed between 20 and 35 weeks of gestation for microbiological studies. Patients were excluded if they met the following criteria: (i) singleton gestation; (ii) episode of preterm labor and intact or ruptured membranes; and (iii) transabdominal amniocentesis performed between 20 and 35 weeks of gestation for microbiological studies. Patients were excluded if chromosomal or structural fetal anomalies or placenta previa was present. All patients provided written informed consent. The use of biological specimens and clinical data for research purposes was approved by the Institutional Review Boards of NICHD and Wayne State University.

2.2 | Biological samples and analysis

Amniotic fluid was transported in a capped sterile syringe to the clinical laboratory where it was cultured for aerobic and anaerobic bacteria, including genital mycoplasmas. Evaluations of the white blood cell count, glucose concentration, and Gram stain of the amniotic fluid were performed shortly after collection. Amniotic fluid was centrifuged
amniotic inflammation was defined as ≥2.2 ng/mL, which is above the 95th percentile among patients with uncomplicated term deliveries.169

Chronic placental inflammatory lesions included the amniotic fluid CXCL10 concentration as a marker of subclinical intra-amniotic inflammation and/or an increase in amniotic fluid IL-6 concentration: (i) normal the combination of MIAC and intra-amniotic inflammation. An elevated amniotic fluid CXCL10 concentration as a marker of subclinical intra-amniotic inflammation was defined as ≥2.2 ng/mL, which is above the 95th percentile among patients with uncomplicated term deliveries.169

The diagnosis of acute histologic chorioamnionitis was based on the presence of acute inflammatory changes in the extraplacental chorioamnion membrane roll and/or chorionic plate of the placenta, using the criteria previously described.188–190,192,196,216,217 The grading and staging of placental lesions consistent with amniotic fluid infection was defined according to the Amniotic Fluid Infection Nosology Committee of the Perinatal Section of the Society for Pediatric Pathology as reported by Redline et al.188 Acute funisitis was defined as the presence of neutrophils in the wall of the umbilical vessels and/or Wharton’s jelly.188,196,197 Chronic placental inflammatory lesions included the following: (i) chronic chorioamnionitis; (ii) villitis of unknown etiology (VUE); and (iii) chronic deciduitis. Chronic chorioamnionitis was diagnosed when lymphocytic infiltration into the chorionic trophoblast layer or chorioamniotic connective tissue was observed.14,15,26,218 VUE was defined as the presence of lymphohistiocytic infiltration, in varying proportion, of the placental villous tree.14,219 Chronic deciduitis was diagnosed as the presence of lymphocytic infiltration into the decidua of the basal plate.220 Lesions consistent with maternal anti-fetal rejection proposed by our group included chronic chorioamnionitis, VUE, or chronic deciduitis with plasma cells.14,16

2.3 Clinical definitions

Gestational age was determined by the last menstrual period and confirmed by ultrasound examination, or by ultrasound examination alone if the sonographic determination of gestational age was not consistent with menstrual dating.211 Preterm labor was diagnosed by the presence of at least two regular uterine contractions every 10 minutes in association with cervical changes in patients with a gestational age between 20 and 36 6/7 weeks that led to preterm delivery (defined as birth prior to the 37th week of gestation). Preterm PROM was diagnosed by a sterile speculum examination with documentation of the pooling of amniotic fluid in the vagina in association with a positive nitrazine test and/or positive ferning test when necessary. Elevated amniotic fluid IL-6 concentration (≥2.6 ng/mL) was used to define intra-amniotic inflammation.176,205–208,212–215 MIAC was defined as a positive amniotic fluid culture. Intra-amniotic infection was defined as the combination of MIAC and intra-amniotic inflammation. An elevated amniotic fluid CXCL10 concentration as a marker of subclinical intra-amniotic inflammation was defined as ≥2.2 ng/mL, which is above the 95th percentile among patients with uncomplicated term deliveries.169

The diagnosis of acute histologic chorioamnionitis was based on the presence of acute inflammatory changes in the extraplacental chorionic membrane roll and/or chorionic plate of the placenta, using the criteria previously described.188–190,192,196,216,217 The grading and staging of placental lesions consistent with amniotic fluid infection was defined according to the Amniotic Fluid Infection Nosology Committee of the Perinatal Section of the Society for Pediatric Pathology as reported by Redline et al.188 Acute funisitis was defined as the presence of neutrophils in the wall of the umbilical vessels and/or Wharton’s jelly.188,196,197 Chronic placental inflammatory lesions included the following: (i) chronic chorioamnionitis; (ii) villitis of unknown etiology (VUE); and (iii) chronic deciduitis. Chronic chorioamnionitis was diagnosed when lymphocytic infiltration into the chorionic trophoblast layer or chorioamniotic connective tissue was observed.14,15,26,218 VUE was defined as the presence of lymphohistiocytic infiltration, in varying proportion, of the placental villous tree.14,219 Chronic deciduitis was diagnosed as the presence of lymphocytic infiltration into the decidua of the basal plate.220 Lesions consistent with maternal anti-fetal rejection proposed by our group included chronic chorioamnionitis, VUE, or chronic deciduitis with plasma cells.14,16

2.4 Study groups

Participants were allocated into four study groups, according to whether they had an increase in amniotic fluid CXCL10 concentration and/or an increase in amniotic fluid IL-6 concentration: (i) normal amniotic fluid IL-6 and CXCL10 concentrations; (ii) an isolated increase in amniotic fluid IL-6 concentration; (iii) an isolated increase in amniotic fluid CXCL10 concentration; and (iv) an increase in both amniotic fluid IL-6 and CXCL10 concentrations. The cutoff has been derived from previous studies.109,111,169

2.5 Study outcomes

The primary outcome of this study was the presence or absence of acute or chronic chorioamnionitis, defined as (i) the absence of both acute and chronic chorioamnionitis; (ii) acute chorioamnionitis ≥ stage 2 in the absence of chronic chorioamnionitis; (iii) chronic chorioamnionitis in the absence of acute histologic chorioamnionitis ≥ stage 2; and (iv) the presence of both acute (≥ stage 2) and chronic chorioamnionitis. The presence of placental lesions associated with maternal anti-fetal rejection was examined as a secondary outcome.217

2.6 Statistical analysis

The Kolmogorov-Smirnov test was used to assess the normality of arithmetic data distributions. The Kruskal-Wallis test and the Mann-Whitney U test were used to make comparisons among and between groups for arithmetic variables. The chi-square test or Fisher’s exact test was used for comparisons of proportions. Multinomial logistic regression models were fit to examine magnitudes of association with primary and secondary outcomes, adjusting for gestational age at amniocentesis. Statistical analysis was performed using SAS 9.4 (Cary, NC, USA). Confidence intervals (95% CI) that do not include the null hypothesis (ie, an odds ratio [OR] of “1.0”) are considered statistically significant.

3 RESULTS

3.1 Clinical characteristics

One hundred and sixty-eight women with either preterm labor with intact membranes (72%) or preterm PROM (28%) were included in this study. Table 1 displays the clinical characteristics of the participants; 88% were African American, 34% were nulliparous, and 83% delivered preterm (<37 weeks of gestation). The median gestational age at amniocentesis was 30 weeks (interquartile range: 27-32 weeks), and amniotic fluid cultures were positive in 20% of the study participants. Placental lesions associated with acute and chronic histologic chorioamnionitis and maternal anti-fetal rejection were observed in 49% (82/168), 27% (45/168), and 41% (69/168) of the study population, respectively.

3.2 Amniotic fluid CXCL10 and IL-6 concentrations according to placental pathologic lesions and outcome of pregnancy

Amniotic fluid CXCL10 concentrations were highest in patients with chronic chorioamnionitis (Figure 1), whereas amniotic fluid IL-6 concentrations were highest in patients with acute chorioamnionitis...
TABLE 1 Descriptive characteristics of the study population

| Descriptive characteristics | Median (IQR) or % (n) |
|-----------------------------|-----------------------|
| Maternal age (y)            | 24.0 (20.3-30.0)      |
| Body mass index (kg/m²)     | 25.0 (21.0-30.9)      |
| Nulliparity (%)             | 33.9% (57/168)        |
| Gestational age at amniocentesis (wk) | 30.2 (26.6-32.3)    |
| African American ethnicity (%) | 88.1% (148/168)       |
| Amniotic fluid WBC count (cells/mm³) | 3.5 (0-39.3)         |
| Amniotic fluid glucose (mg/dL) | 23.0 (10.0-30.0)     |
| Positive amniotic fluid culture (%) | 20.2% (34/168)      |
| Amniocentesis-to-delivery interval (d) | 4 (1-26.8)          |
| Preterm delivery (%)        | 83.3% (140/168)       |
| Gestational age at delivery (wk) | 32.1 (27.7-34.9)     |
| Birthweight (g)             | 1822.5 (1086.3-2472.5) |
| Acute histologic chorioamnionitis (%) | 48.8% (82/168)    |
| Chronic chorioamnionitis (%) | 26.8% (45/168)       |
| Placental lesions associated with maternal anti-fetal rejection (%)* | 41.1% (69/168)      |

Data presented as median (IQR) or % (n). IQR, interquartile range; WBC, white blood cell.
*Placental lesions associated with maternal anti-fetal rejection: chronic chorioamnionitis, villitis of unknown etiology (VUE), and chronic deciduitis with plasma cells.

3.3 Acute and chronic chorioamnionitis in relationship to amniotic fluid concentrations of CXCL10 and IL-6

The prevalence of chronic chorioamnionitis was highest in patients with an isolated elevation in amniotic fluid CXCL10 concentration (46.7%; 14/30) and was lowest in those with an isolated elevation in amniotic fluid IL-6 concentration (7.7%; 2/26) (Table 2). In contrast, the prevalence of acute chorioamnionitis ≥stage 2 was highest in patients with an isolated elevation in both amniotic fluid CXCL10 (≥2.2 ng/mL) and amniotic fluid IL-6 (≥2.6 ng/mL) was observed in 35% (59/168) of the patients, whereas 18% (30/168) had an isolated elevation in the concentration of amniotic fluid CXCL10. 15% (26/168) had an isolated elevation in the concentration of amniotic fluid IL-6, and 32% (53/168) did not have an elevation in amniotic fluid concentrations of either CXCL10 or IL-6. All patients with elevated concentrations of both amniotic fluid CXCL10 and IL-6 delivered before 37 weeks of gestation. By contrast, 93% (24/26) of patients with an isolated elevation in the concentration of amniotic fluid IL-6 and 77% (23/30) of those with an isolated elevation in the concentration of amniotic fluid CXCL10 delivered preterm.

FIGURE 1 The median concentration of AF CXCL10 in patients according to the presence or absence of acute chorioamnionitis (≥stage 2) or chronic chorioamnionitis. The median (interquartile range: IQR) concentration of AF CXCL10 (ng/mL) was highest in patients with chronic chorioamnionitis. The median (IQR) concentration of AF CXCL10 (ng/mL) was 1.6 (0.9-3.4), 3.1 (1.1-6.9), 4.1 (1.9-7.7), and 3.9 (3.0-9.7) in patients with neither acute chorioamnionitis nor chronic chorioamnionitis, acute chorioamnionitis (≥stage 2), chronic chorioamnionitis, and acute and chronic chorioamnionitis, respectively. AF, amniotic fluid; CXCL, C-X-C motif chemokine; acute chorioamnionitis, the presence of acute chorioamnionitis ≥stage 2 in the absence of chronic chorioamnionitis; chronic chorioamnionitis, the presence of chronic chorioamnionitis in the absence of acute chorioamnionitis ≥stage 2.
FIGURE 2 The median concentration of AF IL-6 in patients with acute chorioamnionitis ≥stage 2 and/or chronic chorioamnionitis. The median (interquartile range: IQR) AF concentration of IL-6 (ng/mL) was highest in patients with acute chorioamnionitis ≥stage 2. The median (IQR) AF concentration of IL-6 (ng/mL) was 1.5 (0.6-4.2), 41.6 (5.3-20.7), 1.6 (0.7-5.4), and 17.6 (3.9-167.4) in patients with neither acute nor chronic chorioamnionitis, acute chorioamnionitis, chronic chorioamnionitis, or acute and chronic chorioamnionitis, respectively. AF: amniotic fluid; IL: interleukin; acute chorioamnionitis, the presence of acute chorioamnionitis ≥stage 2 in the absence of chronic chorioamnionitis; chronic chorioamnionitis, the presence of chronic chorioamnionitis in the absence of acute chorioamnionitis ≥stage 2; *P value <.05

(≥stage 2) and chronic chorioamnionitis (OR: 9.6, 95% CI: 3.1-30; and OR: 3.8, 95% CI: 1.3-11.6, respectively). None of the patients whose placentas had both acute (≥stage 2) and chronic chorioamnionitis (n=6) had normal amniotic fluid CXCL10 and IL-6 concentrations.

The magnitudes of association observed between the study groups are shown in Figure 4 in accord with the concentrations of both amniotic fluid CXCL10 and IL-6 as well as the placental lesions associated with maternal anti-fetal rejection. Patients with an elevation in amniotic fluid CXCL10 concentration were significantly more likely to have placental lesions associated with maternal anti-fetal rejection, but not acute chorioamnionitis (≥stage 2), than those with normal amniotic fluid CXCL10 and IL-6 concentrations, adjusting for gestational age at amniocentesis (OR: 3.7, 95% CI: 1.3-10.4; and OR: 1.6, 95% CI: 0.3-8.3, respectively).

The combination of both acute chorioamnionitis (≥stage 2) and placental lesions associated with maternal anti-fetal rejection was not observed in patients without an elevation in amniotic fluid IL-6 and CXCL10 concentrations (Figure 4).

4 | DISCUSSION

4.1 | Principal findings of the study

(i) An isolated elevation in amniotic fluid CXCL10 concentration is associated with chronic, but not acute (≥stage 2), histologic chorioamnionitis; (ii) in contrast, an isolated elevation in amniotic fluid IL-6 concentration was associated with acute (≥stage 2), but not chronic, histologic chorioamnionitis; (iii) similar findings were observed in relation to placental lesions associated with maternal anti-fetal rejection (chronic chorioamnionitis, VUE, and/or chronic deciduitis with plasma cells). Specifically, an isolated elevation in amniotic fluid CXCL10 concentration is associated with the subsequent delivery of placentas with lesions consistent with maternal anti-fetal rejection but not acute histologic chorioamnionitis (≥stage 2); (iv) elevation in both CXCL10 and IL-6 is associated with acute and chronic inflammatory lesions of the placenta, as well as the combination of lesions suggesting that a complex pathologic state representing a mixture of maternal anti-fetal rejection and infection may lead to early preterm delivery in these cases; and (v) all patients with elevated AF concentrations of both CXCL10 and IL-6 delivered prematurely.

4.2 | Two types of intra-amniotic inflammation in preterm labor

4.2.1 | Microbial-associated and sterile intra-amniotic inflammation

Preterm parturition is a syndrome caused by multiple etiologies. Intra-amniotic infection is present in one of every three preterm deliveries and is even more frequent in cases of spontaneous preterm labor with intact membranes. Microorganisms are detected in the amniotic cavity in 25-40% of patients with preterm labor and intact membranes who deliver preterm and in 50-75% of those with preterm PROM at the time of labor onset.

The earlier the gestational age at presentation, the greater the risk of MIAC or intra-amniotic infection. Preterm labor/PROM have no evidence of MIAC, suggesting the important role of sterile inflammation of the amniotic cavity. Using a combination of cultivation and molecular techniques, we have previously reported that only a fraction of all patients with intra-amniotic inflammation (defined as an increase in amniotic fluid IL-6 concentration) have microorganisms present in the amniotic cavity; therefore, sterile intra-amniotic fluid inflammation has emerged as an important mechanism of disease in preterm labor. Danger signals released during the course of cellular stress, necrosis, pyroptosis, and senescence as well as other non-microbial injury can trigger an inflammatory response characterized by secretion of IL-6 and IL-1β from human fetal membranes, suggesting a role for the inflammasomes in the mechanisms leading to premature labor in cases of sterile inflammation. Thus, this mechanism may be involved in patients with sterile intra-amniotic inflammation.
| Outcomes                                                                 | Normal AF IL-6 and CXCL10 (n=53) | Isolated increase in AF IL-6 (n=26) | Isolated increase in AF CXCL10 (n=30) | Increase in both AF IL-6 and CXCL10 (n=59) |
|-------------------------------------------------------------------------|-----------------------------------|-------------------------------------|---------------------------------------|--------------------------------------------|
| GA at amniocentesis (wk)                                                | 31.3 (28.4-32.7)                  | 30.6 (26.7-32.4)*                   | 31.4 (29.4-32.2)*                      | 26.9 (23.6-30.7)                           |
| GA at delivery (wk)                                                    | 34.9 (32.0-38.1)                  | 31.0 (27.1-33.0)*                   | 34.1 (31.8-36.5)*                      | 27.9 (24.3-32.1)                           |
| Preterm delivery (83.3%; n=140/168)                                    | 64.2% (34/53)                     | 93.3% (24/26)*                      | 76.7% (23/30)*                         | 100% (59/59)                               |
| Spontaneous preterm delivery within 48 h of amniocentesis (36.3%; n=61/168) | 20.8% (11/53)                     | 61.5% (16/26)                       | 20.0% (6/30)*                          | 47.5% (28/59)                              |
| Spontaneous preterm delivery before 34 wk of gestation (50.6%; n=85/168) | 30.2% (16/53)                     | 65.4% (17/26)                       | 26.7% (8/30)*                          | 74.6% (44/59)                              |
| Birthweight (g)                                                        | 2485 (1900-2941)                  | 1557 (1008-2119)*                   | 2210 (1701-2743)                       | 1155 (600-1700)                            |
| Placental pathology                                                     |                                   |                                     |                                       |                                            |
| No acute/chronic chorioamnionitis (41.7%; n=70/168)                    | 67.9% (36/53)                     | 50% (13/26)*                        | 36.7% (11/30)*                         | 16.9% (10/59)                              |
| Acute chorioamnionitis ≥stage 2 (31.5%; n=53/168)                      | 13.2% (7/53)                      | 42.3% (11/26)                       | 13.3% (4/30)*                          | 52.5% (31/59)                              |
| Chronic chorioamnionitis (23.2%; n=39/168)                             | 18.9% (10/53)                     | 7.7% (2/26)                         | 46.7% (14/30)*                         | 22.0% (13/59)                              |
| Acute ≥stage 2 and chronic chorioamnionitis (3.6%; n=6/168)            | 0% (0/53)                         | 0% (0/26)                           | 3.3% (1/30)                            | 8.5% (5/59)                                |
| Acute funisitis (33.3%; n=56/168)                                      | 17% (9/53)                        | 34.6% (9/26)                        | 20% (6/30)*                            | 54.2% (32/59)                              |

AF, amniotic fluid; CXCL, C-X-C motif chemokine; GA, gestational age; IL, interleukin; acute chorioamnionitis, the presence of acute chorioamnionitis ≥stage 2 in the absence of chronic chorioamnionitis; chronic chorioamnionitis, the presence of chronic chorioamnionitis in the absence of acute chorioamnionitis ≥stage 2.

Data presented as % (n) or median (interquartile). Normal AF IL-6 and CXCL10 concentrations: IL-6 <2.6 ng/mL and CXCL10 <2.2 ng/mL; isolated increase in AF IL-6 concentrations: IL-6 ≥2.6 ng/mL; isolated increase in AF CXCL10 concentrations: CXCL10 ≥2.2 ng/mL; increase in both AF IL-6 and CXCL10 concentrations: IL-6 ≥2.6 ng/mL and CXCL10 ≥2.2 ng/mL.

*P<.05 for the comparison between the group of isolated increase in amniotic fluid IL-6 concentration and the group of increase in both amniotic fluid IL-6 and CXCL10 concentrations.

**P<.05 for the comparison between the group of isolated increase in amniotic fluid CXCL10 concentration and the group of increase in both amniotic fluid IL-6 and CXCL10 concentrations.
inflammation characterized by elevated amniotic fluid IL-6 concentrations and acute histologic chorioamnionitis. Moreover, a fraction of patients included in this study had elevated concentrations of amniotic fluid IL-6 and CXCL10; these patients delivered preterm and had an odds ratio of 10.9 for acute histologic chorioamnionitis and 4.3 for placental lesions consistent with maternal anti-fetal rejection. The role of the interaction between the acute inflammatory processes that activate the inflammasome and involve fetal rejection is yet to be discovered.

When bacteria and other microorganisms are present in the amniotic cavity and elicit an inflammatory response, a wide range of chemokines and cytokines, such as IL-8, monocyte chemotactic protein-1, macrophage inflammatory protein-1α, growth-regulated oncogene (GRO)-α, and other inflammation-related proteins are produced, and this can result in the chemotaxis of inflammatory cells to the chorioamniotic membranes. Among these inflammation-related proteins, IL-6 has become the key cytokine for the diagnosis of intra-amniotic inflammation because its increase in concentration has been associated with a shorter interval to delivery and an increased rate of neonatal morbidity and mortality.

Recently, an in-depth analysis of the chemokine network in preterm labor with and without inflammation, sterile inflammation, and intra-amniotic infection has been reported. Network analysis provides a greater level of insight into the biology of the process, given that the protein inflammatory process operates through a network rather than single molecules. Collective evidence suggests that CXCL10 plays an important role in the pathogenesis of graft failure and rejection in other organ systems. Overexpression of this T-cell chemokine has been observed in the serum/plasma, urine, and tissue biopsies from patients who experienced rejection in cases of kidney and vascular

| Normal AF IL-6 and CXCL10 | 32% (53/168) | Reference | Reference |
|--------------------------|--------------|-----------|-----------|
| Isolated increase of AF IL-6 | 15% (26/168) | 0.5 (0.1-2.8) | 4.2 (1.3-13.7) |
| Isolated increase of CXCL10 | 18% (30/168) | 4.8 (1.7-14) | 2.1 (0.5-8.9) |
| Increased AF IL-6 and CXCL10 | 35% (59/168) | 3.8 (1.3-11.6) | 9.6 (3.1-30.1) |

Data presented as odds ratio (95% confidence interval)

**FIGURE 3** Magnitudes of association between the study groups according to amniotic fluid IL-6 and CXCL10 concentrations and the presence or absence of acute (≥ stage 2) or chronic chorioamnionitis. Results were obtained by fitting a multinomial logistic regression model and adjusting for gestational age at amniocentesis. AF, amniotic fluid; CXCL, C-X-C motif chemokine; IL, interleukin. Normal AF IL-6 and CXCL10 concentrations: IL-6 < 2.6 ng/mL and CXCL10 < 2.2 ng/mL; isolated increase in AF IL-6 concentration: IL-6 ≥ 2.6 ng/mL and isolated increase in AF CXCL10 concentration: CXCL10 ≥ 2.2 ng/mL; increase in both AF IL-6 and CXCL10 concentrations: IL-6 ≥ 2.6 ng/mL and CXCL10 ≥ 2.2 ng/mL. Acute chorioamnionitis: the presence of acute chorioamnionitis ≥ stage 2 in the absence of chronic chorioamnionitis; chronic chorioamnionitis: the presence of chronic chorioamnionitis in the absence of acute chorioamnionitis ≥ stage 2. None of the patients grouped by their normal AF IL-6 and CXCL10 concentrations had both acute and chronic placental inflammatory lesions; therefore, the computation of the odds ratios relative to the common reference cannot be performed. Red values indicate statistically significant associations between the study group on the left and the outcome named in the column header.

4.2.2 | A novel form of intra-amniotic inflammation characterized by CXCL10

We previously identified a form of intra-amniotic inflammation characterized by an increase in CXCL10 concentration associated with chronic chorioamnionitis, the most common placental lesion in late spontaneous preterm delivery. This form of intra-amniotic inflammation is considered a manifestation of maternal anti-fetal rejection, as an infectious cause has not been identified by the use of cultivation and molecular methods. Compelling evidence suggests that CXCL10 plays an important role in the pathogenesis of graft failure and rejection in other organ systems. Overexpression of this T-cell chemokine has been observed in the serum/plasma, urine, and tissue biopsies from patients who experienced rejection in cases of kidney, heart, lung, and vascular
Moreover, there is a significant correlation between serum/plasma CXCL10 concentrations and the timing and severity of allograft rejection.286–288

In chronic chorioamnionitis, which can be considered a form of allograft rejection, there is an upregulation of CXCL9, CXCL10, and CXCL11 mRNA expression in the chorioamniotic membranes.15 Upregulation of CXC chemokines for CXCR3+ (receptor for T-cell chemokines) cells in the chorioamniotic membranes is associated with a higher median amniotic fluid T-cell chemokine (CXCL10) concentration, and also chronic chorioamnionitis, presumably by stimulating amniotrophic maternal T-cell migration to the chorioamniotic membranes.15 This placental lesion represents a manifestation of maternal anti-fetal rejection as demonstrated by: (i) higher maternal anti-fetal human leukocyte antigen (HLA) sensitization18 in patients with chronic chorioamnionitis than in those without this lesion; (ii) complement deposition (C4d), a surrogate marker of antibody-mediated rejection, in the umbilical vein;16,23,24 and (iii) the presence of a novel form of fetal systemic inflammation (FIRS type 2) in the setting of chronic chorioamnionitis. The transcriptome of the umbilical cord blood in FIRS type 2 is different from that of FIRS type 1, indicating that this is a different condition.21 Moreover, a proteomic analysis of the amniotic fluid from patients with chronic chorioamnionitis demonstrated that these patients have lower amniotic fluid concentrations of glycodefin-A,289 a protein implicated in the maintenance of maternal tolerance against a semiallogeneic fetus.290

Interestingly, approximately 40% of placentas with chronic chorioamnionitis from patients with preterm labor or preterm PROM have concomitant VUE and chronic deciduitis with plasma cells.15 We demonstrated the systemic derangement of the chemokine concentrations that occurred in the maternal and fetal circulation systems of patients with VUE, which was distinct from that observed in the setting of acute chorioamnionitis.14 The mRNA expression of a subset of chemokines and their receptors (CXCL9, CXCL10, CXCL11, CXCL13, and CXCR3) was also higher in VUE placentas than in normal placentas.14 Moreover, the median concentrations of CXCL9, CXCL10, and CXCL11 in maternal and fetal plasma were higher in patients with VUE than in those without this lesion.14 Therefore, we also consider VUE as a manifestation of maternal anti-fetal rejection unless a microorganism can be identified.

In summary, intra-amniotic inflammation associated with maternal anti-fetal rejection differs from microbial-associated intra-amniotic inflammation; it is characterized by an elevation in T-cell chemokine concentration in the amniotic fluid and chorioamniotic membranes as well as the presence of chronic inflammatory lesions of the placenta.

![Figure 4](image-url)
4.3 | CXCL10: a biomarker for chronic placental inflammatory lesions

The results of the study herein support the view that CXCL10 is a marker for chronic inflammatory lesions of the placenta. Our findings are consistent with those of Gervasi et al., who reported that mid-trimester amniotic fluid CXCL10 concentrations >502 pg/mL were associated with late (>32 weeks) spontaneous preterm delivery (OR: 3.9; 95% CI: 1.6-9.9), whereas elevated amniotic fluid IL-6 concentrations (>1740 pg/mL) were associated with a higher risk of spontaneous preterm delivery prior to 32 weeks of gestation (OR: 9.5; 95% CI: 2.9-31.1). Our study differs in that we examined the relationship between the isolated elevation in either amniotic fluid CXCL10 or amniotic fluid IL-6 concentration and the association with both acute and chronic histologic chorioamnionitis.

4.4 | What is the significance of an elevation in the concentrations of amniotic fluid IL-6 and CXCL10?

Thirty-five percent (59/168) of patients in this study had elevated amniotic fluid concentrations of both IL-6 and CXCL10. All of them had spontaneous preterm delivery <37 weeks and <34 weeks of gestation, respectively, suggesting a severe inflammatory process associated with preterm delivery. Moreover, patients with an elevation in both amniotic fluid IL-6 and CXCL10 concentrations had a significantly higher frequency of spontaneous preterm delivery within 48 hours of amniocentesis than those with an isolated elevation in amniotic fluid CXCL10 concentration (Table 2). Indeed, a systemic fetal inflammatory response (defined as the presence of funisitis or chorionic vasculitis) was detected in 54.2% (32/59) of patients with an elevation in both amniotic fluid CXCL10 and IL-6 concentrations, but in only 34.6% (9/26) and 20% (6/30) of patients with an isolated elevation in amniotic fluid IL-6 or CXCL10 concentration, respectively (Table 2). One interpretation proposes that patients with a combination of increased amniotic fluid IL-6 and CXCL10 concentrations had a more severe form of intra-amniotic inflammation than those with an isolated elevation in either CXCL10 or IL-6 concentration, in whom the clinical course leading to preterm delivery may be more indolent in nature. This could explain the trend toward a more frequent involvement of the fetus in patients with an elevation in both amniotic fluid CXCL10 and IL-6 concentrations.

CXCL10 has been implicated in the pathophysiology of sepsis by recruiting neutrophils, macrophages, and T cells. Previous studies demonstrated that there is an upregulation of CXCL10 leading to subsequent activation of its receptor (CXCR3) during infection and inflammation. In an experimental model of septic shock induced by cecal ligation and puncture, it has been shown that plasma and peritoneal fluid CXCL10 concentrations increase. Additionally, CXCL10 knockout mice and wild-type mice treated with anti-CXCL10 IgG antibody had less cytokine production and increased survival. Similar observations were found for the role of CXCR3 during sepsis; it regulates NK- and T-cell trafficking. Moreover, in a septic shock model for mice, the blockade of CXCR3 decreases systemic inflammation and improves survival. CXCL10 and CXCR3 also play a role in human sepsis, and plasma CXCL10 is a predictor of septic shock. Collectively, these data suggest that CXCL10 is an inflammatory mediator involved in the response to microorganisms and bacterial products; therefore, some cases of advanced infections could have elevated concentrations of both IL-6 and CXCL10. An elevated amniotic fluid concentration of CXCL10 would be more meaningful to identify the patient at risk of chronic inflammatory lesions of the placenta if the amniotic fluid concentration of IL-6 is not elevated.

4.5 | Strengths and limitations

The major strengths of this study are as follows: pathologists were blinded to the obstetrical diagnoses and outcomes; standardized protocols were utilized for placental examinations; and the consideration of isolated rather than any increase in the concentration of either amniotic fluid CXCL10 or amniotic fluid IL-6. Limitations were related to the small sample size. Further studies are required to characterize the temporal relationship between exposure to microbial products or other insults and the amniotic fluid changes in cytokines and chemokines. Moreover, large studies are necessary to determine the diagnostic indices of CXCL10 elevation to identify the patient at risk of chronic placental inflammation.

5 | CONCLUSION

An isolated elevation in amniotic fluid CXCL10 concentration (without a concomitant elevation in IL-6 concentration) is associated with the delivery of a placenta with histologic chronic chorioamnionitis or lesions consistent with maternal anti-fetal rejection, whereas an isolated increase in amniotic fluid IL-6 concentration is associated with the delivery of a placenta with acute histologic chorioamnionitis.

ACKNOWLEDGMENTS

This research was supported, in part, by the Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services (NICHD/NIH/DHHS); and, in part, with Federal funds from NICHD/NIH/DHHS under Contract No. HHSN275201300006C.

CONFLICT OF INTEREST

The authors declare no conflict of interests.

REFERENCES

1. Wilkins I, Creasy RK. Preterm labor. Clin Obstet Gynecol. 1990;33:502-514.
2. Romero R, Mazor M, Munoz H, Gomez R, Galasso M, Sherer DM. The preterm labor syndrome. Ann N Y Acad Sci. 1994;734:414-429.
3. Mazor M, Chaim W, Romero R. [Preterm labor syndrome]. Harefuah. 1995;128:111-116.
4. Romero R, Gomez R, Mazor M, Ghezzi F, Yoon BH. The preterm labor syndrome. In: Elder MG, Romero R, Lamont RF, eds. Preterm Labor. New York: Churchill Livingstone; 1997:29-49.
5. Dudley DJ. Pre-term labor: an intra-uterine inflammatory response syndrome? J Reprod Immunol. 1997;36:93-109.
6. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition syndrome. BJOG. 2006;113(Suppl 3):17-42.
7. Villar J, Papageorgiou AT, Knight HE, et al. The preterm birth syndrome: a prototype phenotypic classification. Am J Obstet Gynecol. 2012;206:119-123.
8. Kramer MS, Papageorgiou A, Culhane J, et al. Challenges in defining and classifying the preterm birth syndrome. Am J Obstet Gynecol. 2012;206:108-112.
9. Goldenberg RL, Gravett MG, Iams JD, et al. The preterm birth syndrome: issues to consider in creating a classification system. Am J Obstet Gynecol. 2012;206:113-118.
10. Blencowe H, Cousens S, Dou D, et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10(Suppl 1):52.
11. Guimarães Filho HA, Araujo Junior E, Pires CR, Nardozza LM, Moron AF. Short cervix syndrome: current knowledge from etiology to the control. Arch Gynecol Obstet. 2013;287:621-628.
12. Romero R, Dev SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345:760-765.
13. Fuzzi B, Rizzo R, Criscuoli L, et al. HLA-G expression in early embryos is a fundamental prerequisite for the obtention of pregnancy. Eur J Immunol. 2002;32:311-315.
14. Kim MJ, Romero R, Kim CJ, et al. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-placental and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease. J Immunol. 2009;182:3919-3927.
15. Kim CJ, Romero R, Kusanovic JP, et al. The frequency, clinical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous preterm birth. Mod Pathol. 2010;23:1000-1011.
16. Lee J, Romero R, Xu Y, et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One. 2011;6:e16806.
17. Lee J, Romero R, Dong Z, et al. Unexplained fetal death has a biological signature of maternal anti-fetal rejection: chronic chorioamnionitis and alloimmune anti-human leukocyte antigen antibodies. Histopathology. 2011;59:928-938.
18. Lee J, Romero R, Xu Y, et al. Maternal HLA panel-reactive antibodies in early gestation positively correlate with chronic chorioamnionitis: evidence in support of the chronic nature of maternal anti-fetal rejection. Am J Reprod Immunol. 2011;66:510-526.
19. Romero R, Whitten A, Korzeniowski SJ, et al. Maternal floor infarction/massive perivillous fibrin deposition: a manifestation of maternal antifetal rejection? Am J Reprod Immunol. 2013;70:285-298.
20. Lee J, Romero R, Xu Y, et al. Detection of anti-HLA antibodies in maternal blood in the second trimester to identify patients at risk of antibody-mediated maternal anti-fetal rejection and spontaneous preterm delivery. Am J Reprod Immunol. 2013;70:162-175.
21. Lee J, Romero R, Chaivorapongsa T, et al. Characterization of the fetal blood transcriptome and proteome in maternal anti-fetal rejection: evidence of a distinct and novel type of human fettal systemic inflammatory response. Am J Reprod Immunol. 2013;70:265-284.
22. Lee J, Kim JS, Park JW, et al. Chronic chorioamnionitis is the most common placental lesion in late preterm birth. Placenta. 2013;34:681-689.
49. Krensky AM. Immunologic tolerance. Pediatr Nephrol. 2001;16:675-679.

50. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today. 1999;20:114-118.

51. Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol. 2002;21:471-495.

52. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266-271.

53. Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol. 2013;31:387-411.

54. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A. Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science. 2012;336:1317-1321.

55. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology. 2004;112:38-43.

56. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. Mol Hum Reprod. 2004;10:347-353.

57. Zenclussen AC, Gerlof K, Zenclussen ML, et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol. 2005;166:811-822.

58. Lee JH, Ulrich B, Cho J, Park J, Kim CH. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol. 2011;187:1778-1787.

59. Ramhorst R, Fraccaroli L, Aldo P, et al. Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells. Am J Reprod Immunol. 2012;67:17-27.

60. Quinn KH, Parast MM. Decidual regulatory T cells in placental pathology and pregnancy complications. Am J Reprod Immunol. 2013;69:533-538.

61. Wilczynski JR, Kalinka J, Radwan M. The role of T-regulatory cells in pregnancy and cancer. Front Biosci. 2008;13:2275-2289.

62. Schumacher A, Zenclussen AC. Regulatory T cells: regulators of life. Eur J Immunol. 2014;44:72-80.

63. Collier A, Cook H, Loewendorf A, Yesayan M, Kahn D. Abstract No. 438 Disruption of maternal tolerance during pregnancy leads to Treg repopulation of the antigenic UPI. Am J Obstet Gynecol. 2015;212:S226-S227.

64. Saifi B, Aflatoonian R, Tajik N, et al. T regulatory markers expression in unexplained recurrent spontaneous abortion. J Matern Fetal Neonatal Med. 2016;29:1175-1180.

65. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248:220-223.

66. McMaster MT, Librach CL, Zhou Y, et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol. 1995;154:3771-3778.

67. Ishitani A, Sageshima N, Lee N, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol. 2003;171:1376-1384.

68. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005;19:681-693.

69. Larsen MH, Hvid TV. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol. 2009;70:1026-1034.

70. Ritsick DR, Bommer C, Braverman J. Abstract: The role of fetomateral MHC class II hystoincompatibility in regulating tolerance of the semi-allogenic fetus. Am J Reprod Immunol. 2014;71:37-38.

71. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281:1191-1193.

72. Kudo Y, Boyd CA. Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochem Biophys Acta. 2000;1500:119-124.

73. Mellor AL, Sivakumur J, Chandler P, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2:64-68.

74. Mellor AL, Chandler P, Lee GK, et al. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol. 2002;57:143-150.

75. Kudo Y. The role of placental indoleamine 2,3-dioxygenase in human pregnancy. Obstet Gynecol Sci. 2013;56:209-216.

76. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol. 1997;158:4122-4128.

77. Uckan D, Steele A, Cherry, et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol Hum Reprod. 1997;3:655-662.

78. Holmes CH, Simpson KL, Wainwright SD, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. J Immunol. 1990;144:3099-3105.

79. Hsi BL, Hunt JS, Atkinson JP. Differential expression of complement regulatory proteins on subpopulations of human trophoblast cells. J Reprod Immunol. 1991;19:209-223.

80. Altemani AM, Norato D, Baumer C. Immunological studies in placentas with villitis of unknown etiology: complement components and immunoglobulins in choriocarcinoid villi. J Perinat Med. 1992;20:129-134.

81. Holmes CH, Simpson KL, Okada H, et al. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Eur J Immunol. 1992;22:1579-1585.

82. Tesedos F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol. 1993;151:1562-1570.

83. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator cry in fetomaternal tolerance. Science. 2000;287:498-501.

84. Richani K, Romero R, Soto E, et al. Unexplained intrauterine fetal death is accompanied by activation of complement. J Perinat Med. 2005;33:296-305.

85. Soto E, Romero R, Richani K, et al. Anaphylatoxins in preterm and term labor. J Perinat Med. 2005;33:306-313.

86. Girardi G, Bulla R, Salmon JE, Tesedos F. The complement system in the pathophysiology of pregnancy. Mol Immunol. 2006;43:68-77.

87. Girardi G. Complement inhibition keeps mothers calm and avoids fetal rejection. Immunol Invest. 2008;37:645-659.

88. Mittal P, Romero R, Tarca AL, et al. Characterization of the myometrial transcriptome and biological pathways of spontaneous human labor at term. J Perinat Med. 2010;38:617-643.

89. Chaiworapongsa T, Romero R, Whitten A, et al. Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsia6. J Perinat Med. 2013:41:485-504.

90. Madan I, Than NG, Romero R, et al. The peripheral whole-blood transcriptome of acute pyelonephritis in human pregnancy. J Perinat Med. 2014:42:31-53.

91. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005;202:231-237.
92. Habicht A, Dada S, Jurewicz M, et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol. 2007;179:5211-5219.

93. D’Addio F, Riella LV, Mfeshe BG, et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 2011;187:4530-4541.

94. Xin L, Ertelt JM, Rowe JH, et al. Cutting edge: committed Th1 CD4+ T cell differentiation blocks pregnancy-induced Foxp3 expression with antigen-specific fetal loss. J Immunol. 2014;192:2970-2974.

95. Knder JM, Jiang TT, Ertelt JM, et al. Cross-generational reproductive fitness enforced by microchimeric maternal cells. Cell. 2015;162:505-515.

96. PrabhuDas M, Bonney E, Caron K, et al. Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nat Immunol. 2015;16:328-334.

97. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004;25:201-209.

98. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:109-118.

99. Tan J, Zhou G. Chemokine receptors and transplantation. Cell Mol Immunol. 2005;2:343-349.

100. Romagnani P. From basic science to clinical practice: use of cytokines and chemokines as therapeutic targets in renal diseases. J Nephrol. 2005;18:229-233.

101. Romagnani P, Crescioli C. CXCL10: a candidate biomarker in transplantation. Clin Chim Acta. 2012;413:1364-1373.

102. Zhang Q, Liu YF, Su ZX, Shi LP, Chen YH. Serum fractalkine and interferon-gamma inducible protein-10 concentrations are early detection markers for acute renal allograft rejection. Transplant Proc. 2014;46:1420-1425.

103. Kim YM, Chaemsaitong P, Romero R, et al. Placental lesions associated with acute atherosis. J Matern Fetal Neonatal Med. 2015;28:1554-1562.

104. Gomez-Lopez N, Hernandez-Santiago S, Lobb AP, Olson DM, Vadillo-Ortega F. Normal and premature rupture of fetal membranes at term delivery differ in regional chemotactic activity and related chemokine/cytokine production. Reprod Sci. 2013;20:276-284.

105. Gong X, Chen Z, Liu Y, Lu Q, Jin Z. Gene expression profiling of the paracrine effects of uterine natural killer cells on human endometrial epithelial cells. Int J Endocrinol. 2014;2014:393707.

106. Romero R, Avila C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in preterm labor. Association with infection. J Clin Invest. 1990;85:1392-1400.

107. Romero R, Sepulveda W, Kenney JS, Archer LE, Allison AC, Sehgal PB. Interleukin 6 determination in the detection of microbial invasion of the amniotic cavity. Ciba Found Symp. 1992;167:205-220; discussion 220-203.

108. Romero R, Yoon BH, Kenney JS, Gomez R, Allison AC, Sehgal PB. Amniotic fluid interleukin-6 determinations are of diagnostic and prognostic value in preterm labor. Am J Reprod Immunol. 1993;30:167-183.

109. Yoon BH, Romero R, Kim CJ, et al. Amniotic fluid interleukin-6: a sensitive test for antenatal diagnosis of acute inflammatory lesions of preterm placenta and prediction of perinatal morbidity. Am J Obstet Gynecol. 1995;172:960-970.

110. Cox SM, Casey ML, MacDonald PC. Accumulation of interleukin-1beta and interleukin-6 in amniotic fluid: a sequela of labour at term and preterm. Hum Reprod Update. 1997;3:517-527.

111. Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol. 1997;177:825-830.

112. Arntzen KJ, Kjøllestad AM, Halgunset J, Vatten L, Austgulen R. TNF- 

113. Hsu CD, Meadough E, Aversa K, et al. Elevated amniotic fluid levels of leukemia inhibitory factor, interleukin 6, and interleukin 8 in intra-amniotic infection. Am J Obstet Gynecol. 1998;179: 1267-1270.

114. Yoon BH, Romero R, Moon JB, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001;185:1130-1136.

115. Yoon BH, Romero R, Moon J, et al. Differences in the fetal interleukin-6 response to microbial invasion of the amniotic cavity between term and preterm gestation. J Matern Fetal Neonatal Med. 2003;13:32-38.

116. Jacobsson B, Mattsby-Baltzer I, Hagberg H. Interleukin-6 and interleukin-8 in cervical and amniotic fluid: relationship to microbial invasion of the chorioamniotic membranes. BJOG. 2005;112:719-724.

117. Holst RM, Mattsby-Baltzer I, Wennerholm UB, Hagberg H, Jacobsson B. Interleukin-6 and interleukin-8 in cervical fluid in a population of Swedish women in preterm labor: relationship to microbial invasion of the amniotic fluid, intra-amniotic inflammation, and preterm delivery. Acta Obstet Gynecol Scand. 2005;84:551-557.

118. Holst RM, Laurini R, Jacobsson B, et al. Expression of cytokines and chemokines in cervical and amniotic fluid: relationship to histological chorioamnionitis. J Matern Fetal Neonatal Med. 2007;20:885-893.

119. Menon R, Camargo MC, Thorsen P, Lombardi SJ, Fortunato SJ. Amniotic fluid interleukin-6 increase is an indicator of spontaneous preterm birth in white but not black Americans. Am J Obstet Gynecol. 2008;198:77-e71-77-e77.

120. Marconi C, de Andrade Ramos BR, Peracoli JC, Donders GG, da Silva MG. Amniotic fluid interleukin-1 beta and interleukin-6, but not interleukin-8 correlate with microbial invasion of the amniotic cavity in preterm labor. Am J Reprod Immunol. 2011;65:549-556.

121. Cobo T, Palacio M, Martinez-Terron M, et al. Clinical and inflammatory markers in amniotic fluid as predictors of adverse outcomes in preterm premature rupture of membranes. Am J Obstet Gynecol. 2011;205:126-e121-126-e128.

122. Combs CA, Gravett G, Garite T, et al. Abstract No. 73: Intramniotic inflammation may be more important than the presence of microbes as a determinant of perinatal outcome in preterm labor. Am J Obstet Gynecol. 2013;208:544.

123. Romero R, Kadar N, Miranda J, et al. The diagnostic performance of the Mass Restricted (MR) score in the identification of microbial invasion of the amniotic cavity or intra-amniotic inflammation is not superior to amniotic fluid interleukin-6. J Matern Fetal Neonatal Med. 2014;27:757-769.

124. Romero R, Miranda J, Chaiworapongs S, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol. 2014;72:458-474.

125. Kacerovsky M, Musilova I, Andrys C, et al. Prelabor rupture of membranes between 34 and 37 weeks: the intraamniotic inflammatory response and neonatal outcomes. Am J Obstet Gynecol. 2014;210:325.e321-325.e310.

126. Kacerovsky M, Musilova I, Hornychova H, et al. Bedside assessment of amniotic fluid interleukin-6 in preterm prelabour rupture of membranes. Am J Obstet Gynecol. 2014;211:385.e1-9.

127. Combs CA, Gravett M, Garite TJ, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am J Obstet Gynecol. 2014;210:125.e121-125.e115.

128. Chaemsaitong P, Romero R, Korzeniewski SJ, et al. A point of care test for the determination of amniotic fluid interleukin-6 and the chemokine CXCL-10/IP-10. J Matern Fetal Neonatal Med. 2015;28:1510-1519.
of membranes; a step toward the early treatment of acute intra-amniotic inflammation/infection. J Matern Fetal Neonatal Med. 2015;1:8.

130. Chaemsaithong P, Romero R, Korzeniewski SJ, et al. A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes. J Matern Fetal Neonatal Med. 2015;1:11.

131. Romero R, Ceska M, Avila C, Mazor M, Behnke E, Lindley I. Neutrophil attractant/activating peptide-1/interleukin-8 in term and preterm parturition. Am J Obstet Gynecol. 1991;165:813-820.

132. Cobo T, Kacerovsky M, Palacio M, et al. Intra-amniotic inflammation and cytokine response in amniotic fluid in a Swedish population of the amniotic cavity. Eur J Obstet Gynecol Reprod Biol. 1998;78:5-10.

133. Hsu CD, Meadough E, Aversa K, Copel JA. The role of amniotic fluid L-selectin, GRO-alpha, and interleukin-8 in the pathogenesis of intraamniotic infection. Am J Obstet Gynecol. 1998;178:428-432.

134. Jacobsson B. Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women in preterm labor. Acta Obstet Gynecol Scand. 2003;82:120-128.

135. Jacobsson B, Mattsby-Baltzer I, Andersch B, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 2003;82:423-431.

136. Figueroa R, Garry D, Elminia A, Patel K, Sehgal PB, Tejani N. Evaluation of amniotic fluid cytokines in preterm labor and intact membranes. J Matern Fetal Neonatal Med. 2005;18:241-247.

137. Witt A, Berger A, Gruber CJ, Petricevic L, Aparister P, Husslein P. IL-8 concentrations in maternal serum, amniotic fluid and cord blood in relation to different pathogens within the amniotic cavity. J Perinat Med. 2005;33:22-26.

138. Cobo T, Kacerovsky M, Palacio M, et al. Intra-amniotic inflammatory response in subgroups of women with preterm prelabor rupture of the membranes. PLoS One. 2012;7:e43677.

139. Romero R, Brody DT, Oyarzun E, et al. Infection and labor. III. Interleukin-1: a signal for the onset of parturition. Am J Obstet Gynecol. 1989;160:1117-1123.

140. Mitchell MD, Edwin SS, Silver RM, Romero RJ. Potential agonist action of the interleukin-1 receptor antagonist protein: implications for treatment of women. J Clin Endocrinol Metab. 1993;76:1386-1388.

141. Romero R, Manogue KR, Mitchell MD, et al. Infection and labor. IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol. 1989;161:336-341.

142. Romero R, Mazor M, Sepulveda W, Avila C, Copeland D, Williams J. Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol. 1992;166:1576-1587.

143. Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ. Preterm labor is induced by intraamniotic infusions of interleukin-1β and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhuman primate model. Am J Obstet Gynecol. 2006;195:1578-1589.

144. Athayde N, Romero R, Maymon E, et al. Interleukin 16 in pregnancy, parturition, rupture of fetal membranes, and microbial invasion of the amniotic cavity. Am J Obstet Gynecol. 2000;182:135-141.

145. Pacora P, Romero R, Maymon E, et al. Participation of the novel cytokine interleukin 18 in the host response to intra-amniotic infection. Am J Obstet Gynecol. 2000;183:1138-1143.

146. Greig PC, Herbert WN, Robinette BL, Teot LA. Amniotic fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. Am J Obstet Gynecol. 1995;173:1223-1227.

147. Gotsch F, Romero R, Kusanovic JP, et al. The anti-inflammatory limb of the immune response in preterm labor, intra-amniotic infection/inflammation, and spontaneous parturition at term: a role for interleukin-10. J Matern Fetal Neonatal Med. 2008;21:529-547.

148. Maymon E, Romero R, Pacora P, et al. Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. Am J Obstet Gynecol. 2000;183:94-99.

149. Maymon E, Romero R, Chaiworapongsa T, et al. Amniotic fluid matrix metalloproteinase-8 in preterm labor with intact membranes. Am J Obstet Gynecol. 2001;185:1149-1155.

150. Angus SR, Segel SY, Hsu CD, et al. Amniotic fluid matrix metalloproteinase-8 indicates intra-amniotic infection. Am J Obstet Gynecol. 2001;185:1232-1238.

151. Nien JK, Yoon BH, Espinoza J, et al. A rapid MMP-8 bedside test for the detection of intra-amniotic inflammation identifies patients at risk for imminent preterm labor. Am J Obstet Gynecol. 2006;195:1025-1030.

152. Kim KW, Romero R, Park HS, et al. A rapid matrix metalloproteinase-8 bedside test for the detection of intraamniotic inflammation in women with preterm premature rupture of membranes. Am J Obstet Gynecol. 2007;197:291-292 e291-292 e295.

153. Park CW, Lee SM, Park JS, Jun JK, Romero R, Yoon BH. The antenatal identification of funisitis with a rapid MMP-8 bedside test. J Perinat Med. 2008;36:497-502.

154. Park CW, Yoon BH, Kim SM, Park JS, Jun JK. The frequency and clinical significance of intra-amniotic inflammation defined as an elevated amniotic fluid matrix metalloproteinase-8 in patients with preterm labor and low amniotic fluid white blood cell counts. Obstet Gynecol Sci. 2013;56:167-175.

155. Maymon E, Romero R, Pacora P, et al. Evidence for the participation of interstitial collagenase (matrix metalloproteinase 1) in preterm premature rupture of membranes. Am J Obstet Gynecol. 2000;183:914-920.

156. Maymon E, Romero R, Pacora P, et al. A role for the 72 kDa gelatinsase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. J Perinat Med. 2001;29:308-316.

157. Park KH, Chaiworapongsa T, Kim YM, et al. Matrix metalloproteinase 3 in parturition, premature rupture of the membranes, and microbial invasion of the amniotic cavity. J Perinat Med. 2003;31:12-22.

158. Maymon E, Romero R, Pacora P, et al. Matrilysin (matrix metalloproteinase 7) in parturition, premature rupture of membranes, and intrauterine infection. Am J Obstet Gynecol. 2000;182:1545-1553.

159. Locksmith GJ, Clark P, Duff P, Schultz GS. Amniotic fluid matrix metalloproteinase-9 levels in women with preterm labor and suspected intra-amniotic infection. Obstet Gynecol. 1999;94:1-6.

160. Maymon E, Romero R, Pacora P, et al. Evidence of in vivo differential bioavailability of the active forms of matrix metalloproteinases 9 and 2 in parturition, spontaneous rupture of membranes, and intraamniotic infection. Am J Obstet Gynecol. 2000;183:887-894.

161. Harirah H, Donia SE, Hsu CD. Amniotic fluid matrix metalloproteinase-9 and interleukin-6 in predicting intra-amniotic infection. Obstet Gynecol. 2002;99:80-84.
amniotic fluid: relationship to microbial invasion of the amniotic cavity, intra-amniotic inflammation, and preterm delivery. Am J Obstet Gynecol. 2003;189:1161-1167.

165. Esplin MS, Romero R, Chaiworapongsa T, et al. Monocyte chemotactic protein-1 is increased in the amniotic fluid of women who deliver preterm in the presence or absence of intra-amniotic infection. J Matern Fetal Neonatal Med. 2005;17:365-373.

166. Kacerovsky M, Celen P, Vikova B, et al. Amniotic fluid protein profiles of intraamniotic inflammatory response to Ureaplasma spp. and other bacteria. PLoS One. 2013;8:e60399.

167. Jacobsson B, Holst RM, Andersson B, Hagberg H. Monocyte chemotactic protein-2 and -3 in amniotic fluid: relationship to microbial invasion of the amniotic cavity, intra-amniotic inflammation and preterm delivery. Acta Obstet Gynecol Scand. 2005;84:566-571.

168. Mittal P, Romero R, Kusanovic JP, et al. CXCL6 (granulocyte chemotactic protein-2): a novel chemokine involved in the innate immune response of the amniotic cavity. Am J Reprod Immunol. 2008;60:246-257.

169. Gervasi MT, Romero R, Bracalente G, et al. Mid trimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. J Perinat Med. 2012;40:329-343.

170. Nhan-Chang CL, Romero R, Kusanovic JP, et al. The frequency and risk factors of preterm premature rupture of membranes. Am J Obstet Gynecol. 1992;166:1382-1388.

171. Redline RW. Faye-Petersen O, Heller D, Qureshi F, Savell V, Vogler C. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 2003;6:435-448.

172. Redline RW. Placental inflammation. Semin Neonatol. 2004;9:265-274.

173. Redline RW. Infections and other inflammatory conditions. Semin Diagn Pathol. 2007;24:5-13.

174. Kim SM, Romero R, Park JW, Oh KJ, Jun JK, Yoon BH. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. J Matern Fetal Neonatal Med. 2015;28:1500-1509.

175. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015;213:529-552.

176. Torricelli M, Voltoni C, Tosti P, et al. Histologic chorioamnionitis: different histologic features at different gestational ages. J Matern Fetal Neonatal Med. 2014;27:910-913.

177. Kim SM, Romero R, Park JW, Oh KJ, Jun JK, Yoon BH. The relationship between the intensity of intra-amniotic inflammation and the presence and severity of acute histologic chorioamnionitis in preterm gestation. J Matern Fetal Neonatal Med. 2015;28:1500-1509.

178. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015;213:529-552.

179. Kim EN, Kim CJ, Park JW, Yoon BH. Acute funisitis is associated with distinct changes in fetal hematologic profile. J Matern Fetal Neonatal Med. 2015;28:588-593.

180. Lee J, Oh KJ, Park CW, Park JS, Jun JK, Yoon BH. The presence of funisitis is associated with a decreased risk for the development of neonatal respiratory distress syndrome. Placenta. 2011;32:235-240.

181. Lee J, Romero R, Kim SM, et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. J Matern Fetal Neonatal Med. 2016;29:707-720.

182. Mi Lee S, Romero R, Lee KA, et al. The frequency and risk factors of funisitis and histologic chorioamnionitis in pregnant women at term who delivered after the spontaneous onset of labor. J Matern Fetal Neonatal Med. 2011;24:37-42.
221. Romero R, Mazor M, Wu YK, et al. Infection in the pathogenesis of preterm labor. Semin Perinatol. 1988;12:262-279.

222. Romero R, Mazor M. Infection and preterm labor. Clin Obstet Gynecol. 1988;31:553-584.

223. Romero R, Sirtori M, Oyarzun E, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol. 1989;161:817-824.

224. Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am. 1997;11:135-176.

225. Romero R, Gomez R, Chaiworapongsa T, Conoscenti G, Kim JC, Kim YM. The role of infection in preterm labor and delivery. Paediatr Perinat Epidemiol. 2001;15(Suppl 2):41-56.

226. Romero R, Espinoza J, Chaiworapongsa T, Kalache K. Infection and prematurity and the role of preventive strategies. Semin Neonatol. 2002;7:259-274.

227. Leigh J, Garite TJ. Amnioncensis and the management of premature labor. Obstet Gynecol. 1986;67:500-506.

228. Romero R, Avila C, Brekus CA, Morroti R. The role of systemic and intrauterine infection in preterm parturition. Ann N Y Acad Sci. 1991;622:355-375.

229. Gauthier DW, Meyer WJ, Bieniarz A. Correlation of amniotic fluid glucose concentration and intraamniotic infection in patients with preterm labor or premature rupture of membranes. Am J Obstet Gynecol. 1991;165:1105-1110.

230. Coultipp LL, Grossman JH. Evaluation of rapid diagnostic tests in the detection of microbial infection of the amniotic cavity. Am J Obstet Gynecol. 1992;167:1231-1242.

231. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol. 1992;79:351-357.

232. Coultipp LL, Lien JM, Gomez R, Kapernick P, Khoury A, Grossman JH. The value of amniotic fluid interleukin-6 determination in patients with preterm labor and intact membranes in the detection of microbial invasion of the amniotic cavity. Am J Obstet Gynecol. 1994;171:901-911.

233. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev. 2002;8:3-13.

234. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of infection and inflammation in preterm birth. Semin Reprod Med. 2007;25:21-39.

235. Romero R, Quintero R, Oyarzun E, et al. Intraamniotic infection and the onset of labor in preterm premature rupture of the membranes. Am J Obstet Gynecol. 1998;179:661-666.

236. Romero R, Ghidini A, Mazor M, Behnke E. Microbial invasion of the amniotic cavity in premature rupture of membranes. Clin Obstet Gynecol. 1991;34:769-778.

237. Romero R, Gonzalez R, Sepulveda W, et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical incompetence: prevalence and clinical significance. Am J Obstet Gynecol. 1992;167:1086-1091.

238. Romero R, Avila C, Sepulveda W, et al. The role of systemic and intrauterine infection in preterm labor. In: Fuchs A, Fuchs F, Stubblefield P, eds. Preterm Birth: Causes, Prevention, and Management. New York: McGraw-Hill Inc.; 1993:97.

239. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301-305.

240. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol. 2005;17:359-365.

241. Harris HE, Raucci A. Alarming()s news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006;7:774-778.

242. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1-5.

243. Romero R, Espinoza J, Hassan S, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med. 2008;36:388-398.

244. Gotsch F, Romero R, Chaiworapongsa T, et al. Evidence of the involvement of caspase-1 under physiologic and pathologic cellular
stress during human pregnancy: a link between the inflammasome and parturition. J Matern Fetal Neonatal Med. 2008;21:605-616.

245. Chaiworapongsa T, Erez O, Kusanovic JP, et al. Amniotic fluid heat shock protein 70 concentration in histologic chorioamnionitis, term and preterm parturition. J Matern Fetal Neonatal Med. 2008;21:449-461.

246. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science. 2009;323:1683-1684.

247. Piccinini AM, Midwood KS. DAMPenning inflammation by modulating TLR signalling. Mediators Inflamm. 2010:2010.

248. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826-837.

249. Nunez G. Intracellular sensors of microbes and danger. Immunol Rev. 2011;243:5-8.

250. Romero R, Chaiworapongsa T, Savasan ZA, et al. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. J Matern Fetal Neonatal Med. 2012;25:558-567.

251. Bredeson S, DeFord J, Yin H, Papaconstantinou J, Saade G, Menon R. Abstract No. 710: Acetylated HMGB1 in human amniotic fluid as an important factor in premature preterm rupture of the membranes. Am J Obstet Gynecol. 2014;2010:S348.

252. Ahmed AI, Chaemsaiitchon P, Chaiworapongsa T, et al. Abstract No. 599: A receptor for danger signals, advanced glycation and products (RAGE) in fetal inflammation and clinical chorioamnionitis. Am J Obstet Gynecol. 2015;212:5298.

253. Behnia F, Taylor BD, Woodson M, et al. Chorioamniotic membrane senescence: a signal for parturition? Am J Obstet Gynecol. 2015;212:359 e351-359 e316.

254. Behnia F, Saade G, Micheal V, et al. Abstract No. 98: Term fetal membranes and senescence associated secretory phenotype (SASP)-like gene expression: a signal for parturition? Am J Obstet Gynecol. 2015;212:566.

255. Poletti J, Dutta E, Kechichian T, et al. Abstract No. 73: Activation of p38MAPK and senescence in fetal membranes induced by teleomere overhang sequence: a novel mechanism for preterm birth. Am J Obstet Gynecol. 2015;212:551.

256. Dutta E, Kacerovsky M, Behnia F, Kechichian T, Saade G, Menon R. Abstract No. 152: Development of DNA damage foci, loss of lamin B and activation of p38MAPK: classic signs of senescence in human amnionchorion. Am J Obstet Gynecol. 2015;212:592.

257. Montenegro D, Romero R, Pineles BL, et al. Differential expression of the inflammasome components in the fetal inflammatory response syndrome. Reprod Sci. 2007;14:59A-60A.

258. Pineles BL, Romero R, Montenegro D, et al. The inflammasome in human parturition. Reprod Sci. 2007;14:59A.

259. Abrahams VM. The role of the Nod-like receptor family in trophoblast innate immune responses. J Reprod Immunol. 2011;88:112-117.

260. Lappas M. Caspase-1 activation is increased with human labour in foetal membranes and myometrium and mediates infection-induced interleukin-1beta secretion. Am J Reprod Immunol. 2014;71:189-201.

261. Romero R, Gomez-Lopez N, Xu Y, et al. A role of inflammasome in spontaneous labor at term. Abstract presented at 12th World Congress of Perinatal Medicine, 3rd-6th November, 2015, Madrid, Spain; 2015.

262. Gomez-Lopez N, Romero R, Plazyo O, et al. Intra-amniotic administration of HMGB1 induces spontaneous preterm labor and birth. Am J Reprod Immunol. 2016;75:3-7.

263. Plazyo O, Romero R, Unkel R, et al. HMGB1 induces an inflammatory response in the chorioamniotic membranes that is partially mediated by the inflammasome. Biol Reprod. 2016;95:130.

264. Romero R, Gomez R, Galasso M, et al. Macrophage inflammatory protein-1 alpha in term and preterm parturition: effect of microbial invasion of the amniotic cavity. Am J Reprod Immunol. 1994;32:108-113.

265. Dudley DJ, Hunter C, Mitchell MD, Varner MW. Elevations of amniotic fluid macrophage inflammatory protein-1 alpha concentrations in women during term and preterm labor. Obstet Gynecol. 1996;87:94-98.

266. Kusanovic JP, Romero R, Chaiworapongsa T, et al. Amniotic fluid sTREM-1 in normal pregnancy, spontaneous parturition at term and preterm, and intra-amniotic infection/inflammation. J Matern Fetal Neonatal Med. 2010;23:34-47.

267. Wei SQ, Fraser W, Luo ZC. Inflammatory cytokines and spontaneous preterm birth in asymptomatic women: a systematic review. Obstet Gynecol. 2010;116:393-401.

268. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG. 2011;118:1042-1054.

269. Romero R, Grivel JC, Tarca AL, et al. Evidence of perturbations of the cytokine network in preterm labor. Am J Obstet Gynecol. 2015;213:836.e1-836.e18.

270. Rotondi M, Rosati A, Buonamano A, et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant. 2004;4:1446-1474.

271. Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009;9:389-396.

272. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 2006;69:1683-1690.

273. Suthanthiran M, Schwartz JE, Ding R, et al. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369:20-31.

274. Agostini C, Calabrese F, Rea F, et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol. 2001;158:1703-1711.

275. Melter M, Exeni A, Reinders ME, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation. 2001;104:2558-2564.

276. Panzer U, Reinking RR, Steinmetz OM, et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation. 2004;78:1341-1350.

277. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis. 2001;37:518-531.

278. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 2004;65:2390-2397.

279. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation. 2005;79:1215-1220.

280. Segerer S, Bohmig GA, Exner M, Kerjaschki D, Regele H, SchLordorff D. Role of CXCR3 in cellular but not humoral renal allograft rejection. Transpl Int. 2005;18:676-680.

281. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant. 2009;9:1347-1353.

282. Lo DJ, Weaver TA, Kleiner DE, et al. Chemokines and their receptors in human renal allotransplantation. Transplantation. 2011;91:70-77.

283. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation. 2003;75:72-78.

284. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and receptor gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation. 2003;75:2044-2047.
285. Crescioli C, Buonamano A, Scolletta S, et al. Predictive role of pre-transplant serum CXCL10 for cardiac acute rejection. Transplantation. 2009;87:249-255.

286. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemotactant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol. 2002;169:1556-1560.

287. burns WR, Wang Y, Tang PC, et al. Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma-inducible chemokines in rejecting human arteries. Am J Transplant. 2005;5:1226-1236.

288. Shahzad K, Cadeiras M, Memon S, et al. Gene expression signatures of peripheral blood mononuclear cells during the early post-transplant period in patients developing cardiac allograft vasculopathy. J Transplant. 2010;2010:719696.

289. Ogge G, Romero R, Lee DC, et al. Chronic chorioamnionitis displays distinct alterations of the amniotic fluid proteome. J Pathol. 2011;223:553-565.

290. Liou M, Guo S, Hibbert JM, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22:121-130.

291. Herzig DS, Luan L, Bohannon JK, Toliver-Kinsky TE, Guo Y, Sherwood ER. The role of CXCL10 in the pathogenesis of experimental septic shock. Crit Care. 2014;18:R113.

292. Herzig DS, Driver BR, Fang G, Toliver-Kinsky TE, Shute EN, Sherwood ER. Regulation of lymphocyte trafficking by CXC chemokine receptor 3 during septic shock. Am J Respir Crit Care Med. 2012;185:291-300.

293. Herzig DS, Guo Y, Fang G, Toliver-Kinsky TE, Sherwood ER. Therapeutic efficacy of CXCR3 blockade in an experimental model of severe sepsis. Crit Care. 2012;16:R168.

294. Ng PC, Li K, Chui KM, et al. IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants. Pediatr Res. 2007;61:93-98.

295. Punyadeera C, Schneider EM, Schaffer D, et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J Emerg Trauma Shock. 2010;3:26-35.

296. Chen HL, Hung CH, Tseng HI, Yang RC. Plasma IP-10 as a predictor of serious bacterial infection in infants less than 4 months of age. J Trop Pediatr. 2011;57:145-151.

How to cite this article: Romero R, Chamsaithong P, Chaiyasit N, et al. CXCL10 and IL-6: Markers of two different forms of intra-amniotic inflammation in preterm labor. Am J Reprod Immunol. 2017;78:e12685. https://doi.org/10.1111/aji.12685

298. Chan T, Gu F. Early diagnosis of sepsis using serum biomarkers. Expert Rev Mol Diagn. 2011;11:487-496.